Citadel Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$117K Sell
16,397
-592,979
-97% -$5.98M ﹤0.01% 12796
2026
Q2
$5.91M Buy
609,376
+593,506
+3,740% +$5.41M ﹤0.01% 4441
2026
Q1
$102K Buy
+15,870
New +$78.5K ﹤0.01% 12005
2025
Q4
– Sell
-798,397
Closed -$2.29M – 14393
2025
Q3
$2.29M Buy
798,397
+644,658
+419% +$1.72M ﹤0.01% 5804
2025
Q2
$232K Buy
153,739
+8,650
+6% +$18.2K ﹤0.01% 10376
2025
Q1
$435K Buy
145,089
+41,454
+40% +$224K ﹤0.01% 8782
2024
Q4
$992K Hold
103,635
– – ﹤0.01% 7040
2024
Q3
$1.52M Buy
+103,635
New +$1.2M ﹤0.01% 6025

Other funds holding ARTV

Citadel Advisors's ARTV Position: Q3 2026 in Review

Citadel Advisors reduced its Artiva Biotherapeutics (ARTV) stake by 97% in Q3 2026, selling an estimated $5.98M and leaving 16,397 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #12796.

Citadel Advisors first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.91M in Q2 2026. 98 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Citadel Advisors held 16,397 shares of Artiva Biotherapeutics worth $117K as of Q3 2026.
  • Citadel Advisors sold 592,979 Artiva Biotherapeutics shares in Q3 2026, an estimated $5.98M.
  • Artiva Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12796 holding.
  • Citadel Advisors first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Citadel Advisors's Artiva Biotherapeutics position peaked at $5.91M in Q2 2026.
  • 98 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.